PMID- 33614784
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20220420
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2021
DP  - 2021
TI  - Mesenchymal Stem Cells: A New Choice for Nonsurgical Treatment of OA? Results 
      from a Bayesian Network Meta-Analysis.
PG  - 6663003
LID - 10.1155/2021/6663003 [doi]
LID - 6663003
AB  - OBJECTIVE: Osteoarthritis (OA) is the most common degenerative joint disease, 
      causing joint pain, stiffness, and even disability. Guidelines recommend 
      intra-articular injections as an alternative treatment to relieve OA symptoms for 
      patients who demonstrate poor tolerability or compliance to oral administration 
      of drugs. Mesenchymal stem cells (MSCs) are a potential treatment for of OA. We 
      conducted this network meta-analysis to comprehensively compare the efficacy and 
      safety between hyaluronic acid (HA), corticosteroids (GCs), platelet-rich plasma 
      (PRP), and MSCs. DESIGN: Systematic review and Bayesian network meta-analysis. 
      Data Sources. Relevant studies, published from January 2000 to January 2020, in 
      the PubMed, Cochrane library, EMBASE, and CKNI databases. METHODS: Bayesian 
      network and conventional meta-analyses were conducted. Pain relief, functional 
      improvement, improvement in joint stiffness, and risk of adverse effects (AEs) 
      were assessed. RESULTS: Twenty-five articles with 4642 patients were included. 
      Overall, MSC therapy was the most effective treatment for pain relief 
      (standardized mean difference compared with placebo = 3.61, 95% CI [1.87 to 
      5.35]). Both MSC and PRP therapies improved every symptom of OA effectively and 
      have an advantage over HA and GCs which are recommended by guidelines. MSCs, PRP, 
      HA, and GCs are tolerated well for patients in long-term treatment of OA compared 
      with placebo. CONCLUSIONS: The results show that MSCs relieve pain, stiffness, 
      and dysfunction due to OA better than PRP, HA, and GCs and are not statistically 
      correlated with greater safety concerns. More high-quality trials are needed to 
      reconfirm the findings of this study, however, standardization of preparation of 
      MSCs and PRP should be investigated in the future.
CI  - Copyright (c) 2021 Ziqin Cao et al.
FAU - Cao, Ziqin
AU  - Cao Z
AUID- ORCID: 0000-0002-2465-5701
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
AD  - Ningxia Geriatric Disease Clinical Research Center, People's Hospital of Ningxia 
      Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region 750001, China.
FAU - Li, Yajia
AU  - Li Y
AUID- ORCID: 0000-0003-4710-087X
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Gao, Fuqiang
AU  - Gao F
AD  - Department of Orthopedics, China-Japan Friendship Hospital, China-Japan 
      Friendship Institute of Clinical Medicine, Chinese Academy of Medical Sciences, 
      Peking Union Medical College, Graduate School of Peking Union Medical College, 
      Beijing, China.
FAU - Wu, Ren
AU  - Wu R
AUID- ORCID: 0000-0002-4128-2257
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Dou, Pengcheng
AU  - Dou P
AUID- ORCID: 0000-0003-3719-4040
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Wang, Wanchun
AU  - Wang W
AUID- ORCID: 0000-0002-0610-4180
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Li, Qiangxiang
AU  - Li Q
AUID- ORCID: 0000-0003-4816-4613
AD  - Ningxia Geriatric Disease Clinical Research Center, People's Hospital of Ningxia 
      Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region 750001, China.
AD  - National Clinical Research Center for Geriatric Disorders of Xiangya Hospital, 
      Central South University (Sub-Center of Ningxia), Yinchuan, Ningxia Hui 
      Autonomous Region 750001, China.
AD  - Hunan People's Hospital, Department of Hunan Institute of Geriatrics, Changsha 
      410002, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210202
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Adrenal Cortex Hormones)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Aged
MH  - Arthralgia/therapy
MH  - Bayes Theorem
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/therapeutic use
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation/adverse effects/methods
MH  - Middle Aged
MH  - Osteoarthritis/*therapy
MH  - Platelet-Rich Plasma
MH  - Treatment Outcome
PMC - PMC7876826
COIS- The authors declare that they do not have any competing interests.
EDAT- 2021/02/23 06:00
MHDA- 2021/05/26 06:00
PMCR- 2021/02/02
CRDT- 2021/02/22 05:58
PHST- 2020/10/09 00:00 [received]
PHST- 2020/12/25 00:00 [revised]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/02/22 05:58 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2021/02/02 00:00 [pmc-release]
AID - 10.1155/2021/6663003 [doi]
PST - epublish
SO  - Biomed Res Int. 2021 Feb 2;2021:6663003. doi: 10.1155/2021/6663003. eCollection 
      2021.